The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP)
Status:
Unknown status
Trial end date:
2020-06-15
Target enrollment:
Participant gender:
Summary
In 2006, Weinberg proposed a hypothesis that iron accumulation was a risk factor for
osteoporosis. Osteoporosis is a common complication in various diseases, such as
hemochromatosis, African hemosiderosis, thalassemia, and sickle cell disease, which all share
iron accumulation as a common denominator. Moreover, a 3-year retrospective longitudinal
study has shown that iron accumulation was also associated with osteoporosis in healthy
adults and especially that it can increase the risk of fractures in postmenopausal women.
Based on these observations, iron chelation therapy may have a promising future in the
treatment of iron accumulation-related osteoporosis by removing iron from the body.
The purpose of this study is to determine whether the addition of the iron chelator,
deferasirox, to standard therapy for postmenopausal osteoporosis, is safe and effective.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Soochow University
Treatments:
Calcium Calcium, Dietary Cholecalciferol Deferasirox Ergocalciferols Vitamin D Vitamins